Public Health Impact of Congenital Toxoplasmosis and Cytomegalovirus Infection in Belgium, 2013: A Systematic Review and Data Synthesis

Congenital toxoplasmosis (CT) and cytomegalovirus infection (cCMV) may cause significant morbidity and even fetal or neonatal mortality. We aimed to quantify the disease burden of CT and cCMV in Belgium in terms of disability-adjusted life years (DALYs) and identify data gaps. The public health impact of CT and cCMV in Belgium in 2013 was 188 (95% uncertainty interval [UI], 43-419) and 1976 (95% UI, 757-4067) DALYs, respectively. The major data gaps identified were representative Belgian studies; information on important sequelae, intrauterine mortality, and termination of pregnancy; and late... Mehr ...

Verfasser: Smit, G. Suzanne A.
Padalko, Elizaveta
Van Acker, Jos
Hens, Niel
Dorny, Pierre
Speybroeck, Niko
Devleesschauwer, Brecht
Dokumenttyp: review
Erscheinungsdatum: 2017
Verlag/Hrsg.: OXFORD UNIV PRESS INC
Schlagwörter: congenital infections / data gaps / burden of disease / DALY
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-28959621
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://hdl.handle.net/1942/24377

Congenital toxoplasmosis (CT) and cytomegalovirus infection (cCMV) may cause significant morbidity and even fetal or neonatal mortality. We aimed to quantify the disease burden of CT and cCMV in Belgium in terms of disability-adjusted life years (DALYs) and identify data gaps. The public health impact of CT and cCMV in Belgium in 2013 was 188 (95% uncertainty interval [UI], 43-419) and 1976 (95% UI, 757-4067) DALYs, respectively. The major data gaps identified were representative Belgian studies; information on important sequelae, intrauterine mortality, and termination of pregnancy; and late onset sequelae. A scenario analysis showed important increases in years of life lost when the burden due to fetal losses was included and decreases in DALYs when comprehensive CT prevention measures were conducted. Addressing the key data gaps identified may allow generation of the data needed to break the vicious circle of underrecognition. ; This work was supported by the Research Foundation-Flanders (FWO Aspirant), Brussels, Belgium. N. H. gratefully acknowledges support from the University of Antwerp Scientific Chair in Evidence-Based Vaccinology, financed in 2009-2016 by a gift from Pfizer and in 2016 from GSK.